Firefly Neuroscience and NeuroSigma joined forces to broaden U.S. access to the Monarch eTNS non-drug ADHD therapy, leveraging Firefly's AI-powered Evoke platform. The collaboration signals potential near-term traction as Monarch expands sales and financing options, supported by biomarker insights from Evoke. The stock moved higher on the news, underscoring a market view of initial revenue upside and broader adoption.
Firefly Neuroscience has significantly expanded its commercial reach and EEG scan volumes, showcasing a more than 20-fold increase. This growth positions the company favorably to further explore AI-driven biomarker discoveries that may enhance treatment options in neuroscience.
U.S. stocks dipped; Nasdaq fell over 100 points. AIFF shares surged 141% after announcing new research advances. U.S. producer prices increased 0.2% in December, lower than expected.
